The archive doesn't name specific menopause startups worth watching. What it does surface is that menopause tech remains early stage. As of 2017, innovation in the space was minimal compared to menstruation and hormonal tracking [Ep 26]. By 2023, venture capital showed growth in women's health investment broadly, but clinical impact remained unclear, with the menopause segment lagging especially [#298][#287].
Stella, a menopause symptom management app, was developed at Vera Health under Dr Michelle Griffin's leadership [#287]. Kamet Ventures mentioned working with an early-stage menopause startup on a novel management approach [#219], but no name or detail was disclosed. The more established players — Flo Health and Bonzun — focus on reproductive health and pregnancy respectively [#262][Ep 44], not menopause.
The deeper pattern: menopause tech struggles from foundational gaps. Without baseline clinical knowledge of menopausal physiology and experience, founders build on unstable ground [#430]. Interest exists; execution lags. If you're evaluating menopause startups, the question isn't which ones to watch, but whether they've solved the evidence problem first.
Search 450+ episodes and 42,000 chunks of healthtech conversation.